Jacques Delaunay

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel et al. · Blood · 2010 · 386 citations · Full text

Medicine, Oncology, Pharmacology +10

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

Éric Jourdan, Nicolas Boissel, Sylvie Chevret et al. · Blood · 2013 · 357 citations

Medicine, Hematology, Oncology +16

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)

Sylvain Thépot, Raphaël Itzykson, Valérie Seegers et al. · Blood · 2010 · 156 citations

Medicine, Hematology, Oncology +17

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

Lionel Adès, Simone Boehrer, Thomas Prébet et al. · Blood · 2008 · 150 citations · Full text

Medicine, Hematology, Oncology +12